Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JANX014 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | JANX014 will be administered at increasing dose levels per cohort to determine the maximum tolerated dose. |
| Dose Expansion | EXPERIMENTAL | Participants will be dosed at levels previously declared tolerable. |
| Name | Type | Description |
|---|---|---|
| JANX014 | BIOLOGICAL | JANX014 will be administered via IV dosing |
Inclusion Criteria: * Male ≥18 years of age at the time of signing informed consent * Histologically or cytologically confirmed adenocarcinoma of the prostate * For Dose Escalation: Having mCRPC that progressed after at least one novel anti-androgen therapy and at least one taxane containing regime...
Top 20 of 49 competitors
JANX014 is an investigational monoclonal antibody being studied for the treatment of prostate cancer, specifically metastatic castration-resistant prostate cancer. It is currently in Phase 1 clinical development and has not been approved by the FDA.
JANX014 targets PSMA, a protein commonly expressed on prostate cancer cells. By binding to PSMA, the antibody is designed to deliver a therapeutic effect directly to the tumor. This mechanism is being evaluated in an ongoing Phase 1 clinical trial.
JANX014 is being developed by Janux Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol JANX. The company is conducting a Phase 1 clinical trial to evaluate the safety and efficacy of JANX014 in patients with metastatic castration-resistant prostate cancer.
JANX014 is in Phase 1 clinical development. It is an investigational drug and has not yet received FDA approval. The ongoing Phase 1 trial is actively recruiting participants with metastatic castration-resistant prostate cancer in the United States.
JANX014 is being studied in a Phase 1 clinical trial with the identifier NCT07545811. This trial, titled 'Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer,' is currently recruiting and aims to enroll 43 male participants aged 18 years and older in the United States.
No alternative names for JANX014 have been disclosed. It is a distinct investigational monoclonal antibody developed by Janux Therapeutics. As of now, it is only known by its code name JANX014 and is not marketed under any other brand name.